NCT04174118View on ClinicalTrials.gov

Study of DCR-A1AT in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 24, 2019

Primary Completion Date

July 6, 2021

Study Completion Date

March 6, 2023

Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
DRUG

belcesiran

belcesiran will be administered subcutaneously (SC) at dose levels planned.

DRUG

Placebo

Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).

Trial Locations (2)

1010

Auckland Clinical Studies, Grafton

Unknown

Clinical Trial Consultants AB, Uppsala

All Listed Sponsors
lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY

NCT04174118 - Study of DCR-A1AT in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter